These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 27055253)

  • 1. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
    Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP-1 promotes autophagy via the AMPK/mTOR pathway in CNE-2 human nasopharyngeal carcinoma cells following ionizing radiation, while inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells.
    Chen ZT; Zhao W; Qu S; Li L; Lu XD; Su F; Liang ZG; Guo SY; Zhu XD
    Mol Med Rep; 2015 Aug; 12(2):1868-76. PubMed ID: 25872765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
    Wang J; He G; Li H; Ge Y; Wang S; Xu Y; Zhu Q
    Eur J Med Chem; 2021 Mar; 213():113054. PubMed ID: 33309164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
    Wang D; Wang M; Jiang N; Zhang Y; Bian X; Wang X; Roberts TM; Zhao JJ; Liu P; Cheng H
    Oncotarget; 2016 Mar; 7(11):13153-66. PubMed ID: 26909613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
    Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
    Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
    Mallon R; Hollander I; Feldberg L; Lucas J; Soloveva V; Venkatesan A; Dehnhardt C; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Gibbons J
    Mol Cancer Ther; 2010 Apr; 9(4):976-84. PubMed ID: 20371716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.